Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

Phase 3

Completed

• Conditions: Major Depressive Disorder

• Registration Number: NCT00034944
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Detailed Description

The duration of treatment is 8 weeks.

Study Timeline

• Study Start: 2002-01-24
• Study First Submitted: 2002-05-02
• Study First Submitted QC: 2002-05-02
• Study First Posted: 2002-05-03
• Primary Completion: 2003-12-17
• Study Completion: 2003-12-17
• Status Verified: 2017-05
• Last Update Submitted: 2017-05-02
• Last Update Posted: 2017-05-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 495

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HAMD-17 total score at week 8. Tolerability.

Secondary Outcome Measures

Name	Time	Method
CGI-I Scale score at week 8 and at least a 50% reduction in the HAMD-17 total score.